{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:50:15Z","timestamp":1792817415486,"version":"4.5.0"},"reference-count":101,"publisher":"Oxford University Press (OUP)","issue":"R1","license":[{"start":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T00:00:00Z","timestamp":1562889600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gene therapy is now being trialled as a therapeutic option for an expanding number of conditions, based primarily on the successful treatment over the past two decades of patients with specific primary immunodeficiencies (PIDs) including severe combined immunodeficiency and Wiskott\u2013Aldrich syndrome and metabolic conditions such as leukodystrophy. The field has evolved from the use of gammaretroviral vectors to more sophisticated lentiviral platforms that offer an improved biosafety profile alongside greater efficiency for hematopoietic stem cells gene transfer. Here we review more recent developments including licensing of gene therapies, use of gene corrected autologous T cells as an alternative strategy for some PIDs and the potential of targeted gene correction using various gene editing platforms. Given the promising results of recent clinical trials, it is likely that autologous gene therapies will become standard of care for a number of devastating diseases in the coming decade.<\/jats:p>","DOI":"10.1093\/hmg\/ddz170","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T19:09:51Z","timestamp":1562612991000},"page":"R15-R23","source":"Crossref","is-referenced-by-count":58,"title":["Gene therapy for primary immunodeficiency"],"prefix":"10.1093","volume":"28","author":[{"given":"Claire","family":"Booth","sequence":"first","affiliation":[{"name":"Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Romano","sequence":"additional","affiliation":[{"name":"Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford School of Medicine, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Roncarolo","sequence":"additional","affiliation":[{"name":"Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford School of Medicine, Stanford, CA, USA"},{"name":"Institute for Stem Cell Biology and Regenerative Medicine (ISCBRM), Stanford School of Medicine, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian J","family":"Thrasher","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,11]]},"reference":[{"key":"2019101710390350900_ref1","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1016\/j.jaci.2009.07.053","article-title":"Primary immunodeficiencies","volume":"125","author":"Notarangelo","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"2019101710390350900_ref2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/ACI.0b013e32835923a6","article-title":"History of primary immunodeficiency diseases","volume":"12","author":"Ochs","year":"2012","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"2019101710390350900_ref3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10875-017-0465-8","article-title":"The 2017 IUIS phenotypic classification for primary immunodeficiencies","volume":"38","author":"Bousfiha","year":"2018","journal-title":"J. Clin. Immunol."},{"key":"2019101710390350900_ref4","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2017.12.980","article-title":"Update: vaccines in primary immunodeficiency","volume":"141","author":"Bonilla","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"2019101710390350900_ref5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13223-018-0290-5","article-title":"Primary immunodeficiency","volume":"14","author":"McCusker","year":"2018","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"2019101710390350900_ref6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"key":"2019101710390350900_ref7","first-page":"162","article-title":"Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency","volume":"5","author":"Al-Herz","year":"2014","journal-title":"Front. Immunol."},{"key":"2019101710390350900_ref8","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jaci.2009.10.013","article-title":"Primary immunodeficiencies: 2009 update","volume":"124","author":"International Union of Immunological Societies Expert Committee on Primary, I","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"2019101710390350900_ref9","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrg3455","article-title":"Sequencing studies in human genetics: design and interpretation","volume":"14","author":"Goldstein","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"2019101710390350900_ref10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2013.09.006","article-title":"The next-generation sequencing revolution and its impact on genomics","volume":"155","author":"Koboldt","year":"2013","journal-title":"Cell"},{"key":"2019101710390350900_ref11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/ng.2892","article-title":"A general framework for estimating the relative pathogenicity of human genetic variants","volume":"46","author":"Kircher","year":"2014","journal-title":"Nat. Genet."},{"key":"2019101710390350900_ref12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10875-017-0455-x","article-title":"Newborn screening for primary immunodeficiency diseases: history, current and future practice","volume":"38","author":"King","year":"2018","journal-title":"J. Clin. Immunol."},{"key":"2019101710390350900_ref13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/1744666X.2018.1459189","article-title":"Clinical considerations in the hematopoietic stem cell transplant management of primary immunodeficiencies","volume":"14","author":"Laberko","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"2019101710390350900_ref14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2014.09.017","article-title":"Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the blood and marrow transplant clinical trials network (BMT CTN)","volume":"21","author":"Howard","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2019101710390350900_ref15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.molmed.2016.02.002","article-title":"Treating immunodeficiency through HSC gene therapy","volume":"22","author":"Booth","year":"2016","journal-title":"Trends Mol. Med."},{"key":"2019101710390350900_ref16","doi-asserted-by":"crossref","first-page":"e9958","DOI":"10.15252\/emmm.201809958","article-title":"Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives","volume":"11","author":"Naldini","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"2019101710390350900_ref17","doi-asserted-by":"crossref","first-page":"456","DOI":"10.2174\/156652310793797739","article-title":"Production of retroviral vectors: review","volume":"10","author":"Coroadinha","year":"2010","journal-title":"Curr. Gene Ther."},{"key":"2019101710390350900_ref18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.2174\/156652310793797748","article-title":"Large-scale production means for the manufacturing of lentiviral vectors","volume":"10","author":"Schweizer","year":"2010","journal-title":"Curr. Gene Ther."},{"key":"2019101710390350900_ref19","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-61779-095-9_1","article-title":"Introduction to viral vectors","volume":"737","author":"Warnock","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"2019101710390350900_ref20","volume-title":"Retroviruses","author":"Coffin","year":"1997"},{"key":"2019101710390350900_ref21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"2019101710390350900_ref22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/hum.1995.6.6-709","article-title":"Gene therapy in Europe","volume":"6","author":"Bordignon","year":"1995","journal-title":"Hum. Gene Ther."},{"key":"2019101710390350900_ref23","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"key":"2019101710390350900_ref24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"2019101710390350900_ref25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2016-01-688226","article-title":"Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"128","author":"Cicalese","year":"2016","journal-title":"Blood"},{"key":"2019101710390350900_ref26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.ymthe.2017.12.022","article-title":"Gene therapy for adenosine deaminase deficiency: a comprehensive evaluation of short- and medium-term safety","volume":"26","author":"Cicalese","year":"2018","journal-title":"Mol. Ther."},{"key":"2019101710390350900_ref27","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J. Clin. Invest."},{"key":"2019101710390350900_ref28","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J. Clin. Invest."},{"key":"2019101710390350900_ref29","doi-asserted-by":"crossref","first-page":"227ra233","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott\u2013Aldrich syndrome\u2014long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"2019101710390350900_ref30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat. Med."},{"key":"2019101710390350900_ref31","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2174\/1566523215666150515145255","article-title":"Successful combination of sequential gene therapy and rescue Allo-HSCT in two children with X-CGD\u2014importance of timing","volume":"15","author":"Siler","year":"2015","journal-title":"Curr. Gene Ther."},{"key":"2019101710390350900_ref32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10545-014-9690-y","article-title":"Lentiviral vectors for the treatment of primary immunodeficiencies","volume":"37","author":"Farinelli","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"2019101710390350900_ref33","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral gene therapy combined with low-dose Busulfan in infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2019101710390350900_ref34","doi-asserted-by":"crossref","first-page":"1233151","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott\u2013Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"2019101710390350900_ref35","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott\u2013Aldrich syndrome","volume":"313","author":"Hacein-Bey Abina","year":"2015","journal-title":"JAMA"},{"key":"2019101710390350900_ref36","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","article-title":"Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott\u2013Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study","volume":"6","author":"Ferrua","year":"2019","journal-title":"Lancet Haematol."},{"key":"2019101710390350900_ref37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jaci.2018.02.053","article-title":"Transfer of gene-corrected T cells corrects humoral and cytotoxic defects in patients with X-linked lymphoproliferative disease","volume":"142","author":"Panchal","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"2019101710390350900_ref38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaci.2014.04.017","article-title":"Reply: to PMID 24522092","volume":"134","author":"Cervenak","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"2019101710390350900_ref39","doi-asserted-by":"crossref","first-page":"335ra357","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"2019101710390350900_ref40","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1182\/blood-2017-04-777136","article-title":"Gene therapy for Wiskott\u2013Aldrich syndrome in a severely affected adult","volume":"130","author":"Morris","year":"2017","journal-title":"Blood"},{"key":"2019101710390350900_ref41","doi-asserted-by":"crossref","first-page":"215ra174","DOI":"10.1126\/scitranslmed.3007320","article-title":"CD4(+) T cells from IPEX patients convert into functional and stable regulatory T cells by FOXP3 gene transfer","volume":"5","author":"Passerini","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"2019101710390350900_ref42","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaci.2017.11.050","article-title":"T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations","volume":"142","author":"Ghosh","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"2019101710390350900_ref43","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1182\/blood-2016-07-729871","article-title":"Gene-corrected human Munc13-4-deficient CD8+ T cells can efficiently restrict EBV-driven lymphoproliferation in immunodeficient mice","volume":"128","author":"Soheili","year":"2016","journal-title":"Blood"},{"key":"2019101710390350900_ref44","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood-2015-11-683235","article-title":"Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome","volume":"127","author":"Hubbard","year":"2016","journal-title":"Blood"},{"key":"2019101710390350900_ref45","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1089\/hum.1993.4.4-513","article-title":"Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID","volume":"4","author":"Bordignon","year":"1993","journal-title":"Hum. Gene Ther."},{"key":"2019101710390350900_ref46","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"key":"2019101710390350900_ref47","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nm0502-423","article-title":"Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement","volume":"8","author":"Aiuti","year":"2002","journal-title":"Nat. Med."},{"key":"2019101710390350900_ref48","doi-asserted-by":"crossref","first-page":"737","DOI":"10.15252\/emmm.201707573","article-title":"Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products","volume":"9","author":"Aiuti","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"2019101710390350900_ref49","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"2019101710390350900_ref50","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"2019101710390350900_ref51","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2019101710390350900_ref52","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2019101710390350900_ref53","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bcmd.2017.12.001","article-title":"Gene therapy and gene editing strategies for hemoglobinopathies","volume":"70","author":"Lidonnici","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"2019101710390350900_ref54","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent beta-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2019101710390350900_ref55","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/biomedicines6040105","article-title":"CRISPR\/Cas9 for cancer therapy: hopes and challenges","volume":"6","author":"Martinez-Lage","year":"2018","journal-title":"Biomedicines"},{"key":"2019101710390350900_ref56","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/mt.2016.10","article-title":"Genome-editing technologies for gene and cell therapy","volume":"24","author":"Maeder","year":"2016","journal-title":"Mol. Ther."},{"key":"2019101710390350900_ref57","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"2019101710390350900_ref58","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/emboj\/21.8.2030","article-title":"Nuclear dynamics of RAD52 group homologous recombination proteins in response to DNA damage","volume":"21","author":"Essers","year":"2002","journal-title":"EMBO J."},{"key":"2019101710390350900_ref59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","article-title":"The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway","volume":"79","author":"Lieber","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"2019101710390350900_ref60","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1101\/gad.280545.116","article-title":"Noncanonical views of homology-directed DNA repair","volume":"30","author":"Verma","year":"2016","journal-title":"Genes Dev."},{"key":"2019101710390350900_ref61","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/genes4030388","article-title":"Replication checkpoint: tuning and coordination of replication forks in s phase","volume":"4","author":"Hustedt","year":"2013","journal-title":"Genes (Basel)"},{"key":"2019101710390350900_ref62","article-title":"The control of DNA repair by the cell cycle","volume":"19","author":"Hustedt","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"2019101710390350900_ref63","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1073\/pnas.81.10.3153","article-title":"Homologous recombination between plasmids in mammalian cells can be enhanced by treatment of input DNA","volume":"81","author":"Kucherlapati","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2019101710390350900_ref64","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1073\/pnas.91.13.6064","article-title":"Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells","volume":"91","author":"Rouet","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2019101710390350900_ref65","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1126\/science.1078395","article-title":"Chimeric nucleases stimulate gene targeting in human cells","volume":"300","author":"Porteus","year":"2003","journal-title":"Science"},{"key":"2019101710390350900_ref66","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev-biochem-060713-035418","article-title":"Genome engineering with targetable nucleases","volume":"83","author":"Carroll","year":"2014","journal-title":"Annu. Rev. Biochem."},{"key":"2019101710390350900_ref67","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1126\/science.1079512","article-title":"Enhancing gene targeting with designed zinc finger nucleases","volume":"300","author":"Bibikova","year":"2003","journal-title":"Science"},{"key":"2019101710390350900_ref68","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nbt.1755","article-title":"A TALE nuclease architecture for efficient genome editing","volume":"29","author":"Miller","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"2019101710390350900_ref69","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"2019101710390350900_ref70","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1017\/S0033583505004063","article-title":"Homing endonuclease structure and function","volume":"38","author":"Stoddard","year":"2005","journal-title":"Q. Rev. Biophys."},{"key":"2019101710390350900_ref71","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1093\/nar\/gkl720","article-title":"A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences","volume":"34","author":"Smith","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"2019101710390350900_ref72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jmb.2007.04.079","article-title":"Engineered I-CreI derivatives cleaving sequences from the human XPC gene can induce highly efficient gene correction in mammalian cells","volume":"371","author":"Arnould","year":"2007","journal-title":"J. Mol. Biol."},{"key":"2019101710390350900_ref73","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10577-014-9450-8","article-title":"Understanding the DNA damage response in order to achieve desired gene editing outcomes in mosquitoes","volume":"23","author":"Overcash","year":"2015","journal-title":"Chromosome Res."},{"key":"2019101710390350900_ref74","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"2019101710390350900_ref75","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1093\/nar\/gkr218","article-title":"Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting","volume":"39","author":"Cermak","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"2019101710390350900_ref76","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"2019101710390350900_ref77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nmeth0111-7a","article-title":"Preassembled zinc-finger arrays for rapid construction of ZFNs","volume":"8","author":"Kim","year":"2011","journal-title":"Nat. Methods"},{"key":"2019101710390350900_ref78","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature11537","article-title":"In vivo genome editing using a high-efficiency TALEN system","volume":"491","author":"Bedell","year":"2012","journal-title":"Nature"},{"key":"2019101710390350900_ref79","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nbt.2170","article-title":"FLASH assembly of TALENs for high-throughput genome editing","volume":"30","author":"Reyon","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"2019101710390350900_ref80","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"2019101710390350900_ref81","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cell.2015.12.035","article-title":"Biology and applications of CRISPR systems: harnessing nature\u2019s toolbox for genome engineering","volume":"164","author":"Wright","year":"2016","journal-title":"Cell"},{"key":"2019101710390350900_ref82","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"2019101710390350900_ref83","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"2019101710390350900_ref84","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"2019101710390350900_ref85","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"2019101710390350900_ref86","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.molcel.2015.04.028","article-title":"Choosing the right tool for the job: RNAi, TALEN, or CRISPR","volume":"58","author":"Boettcher","year":"2015","journal-title":"Mol. Cell"},{"key":"2019101710390350900_ref87","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature.2016.20988","article-title":"CRISPR gene-editing tested in a person for the first time","volume":"539","author":"Cyranoski","year":"2016","journal-title":"Nature"},{"key":"2019101710390350900_ref88","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.omtm.2018.08.003","article-title":"Disruption of the BCL11A erythroid enhancer reactivates fetal hemoglobin in erythroid cells of patients with beta-thalassemia major","volume":"10","author":"Psatha","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2019101710390350900_ref89","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.omtm.2016.12.009","article-title":"Long-term engraftment and fetal globin induction upon BCL11A gene editing in bone-marrow-derived CD34(+) hematopoietic stem and progenitor cells","volume":"4","author":"Chang","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2019101710390350900_ref90","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMra1800729","article-title":"A new class of medicines through DNA editing","volume":"380","author":"Porteus","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2019101710390350900_ref91","doi-asserted-by":"crossref","first-page":"eaan0820","DOI":"10.1126\/scitranslmed.aan0820","article-title":"Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1","volume":"9","author":"Schiroli","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"2019101710390350900_ref92","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41467-019-09614-y","article-title":"Gene correction for SCID-X1 in long-term hematopoietic stem cells","volume":"10","author":"Pavel-Dinu","year":"2019","journal-title":"Nat. Commun."},{"key":"2019101710390350900_ref93","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nbt.3513","article-title":"Targeted gene addition in human CD34(+) hematopoietic cells for correction of X-linked chronic granulomatous disease","volume":"34","author":"De Ravin","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"2019101710390350900_ref94","doi-asserted-by":"crossref","first-page":"eaah3480","DOI":"10.1126\/scitranslmed.aah3480","article-title":"CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease","volume":"9","author":"De Ravin","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"2019101710390350900_ref95","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1056\/NEJMoa1007097","article-title":"Residual NADPH oxidase and survival in chronic granulomatous disease","volume":"363","author":"Kuhns","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2019101710390350900_ref96","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/3233","article-title":"Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice","volume":"4","author":"Brown","year":"1998","journal-title":"Nat. Med."},{"key":"2019101710390350900_ref97","doi-asserted-by":"crossref","first-page":"97ra79","DOI":"10.1126\/scitranslmed.3002715","article-title":"Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"2019101710390350900_ref98","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1172\/JCI90367","article-title":"Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency","volume":"127","author":"Shaw","year":"2017","journal-title":"J. Clin. Invest."},{"key":"2019101710390350900_ref99","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","article-title":"A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency","volume":"371","author":"Hacein-Bey-Abina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"2019101710390350900_ref100","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-05-222760","article-title":"Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils","volume":"115","author":"Kang","year":"2010","journal-title":"Blood"},{"key":"2019101710390350900_ref101","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/mt.2011.166","article-title":"Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I\/II trial","volume":"19","author":"Kang","year":"2011","journal-title":"Mol. Ther."}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/hmg\/advance-article-pdf\/doi\/10.1093\/hmg\/ddz170\/29106680\/ddz170.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/28\/R1\/R15\/30160354\/ddz170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/28\/R1\/R15\/30160354\/ddz170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T06:09:50Z","timestamp":1663913390000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hmg\/article\/28\/R1\/R15\/5531166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,11]]},"references-count":101,"journal-issue":{"issue":"R1","published-online":{"date-parts":[[2019,7,11]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddz170","relation":{},"ISSN":["0964-6906","1460-2083"],"issn-type":[{"value":"0964-6906","type":"print"},{"value":"1460-2083","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,7,11]]}}}